M/s. SUN Pharma ANZ Pty Ltd Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: M/s. SUN Pharma ANZ Pty Ltd Pharmaceutical Import Records from India — 5 Products, $13.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. SUN Pharma ANZ Pty Ltd — Pharmaceutical Importer Profile (2026) | 5 Products, $13.6M Trade | TransData Nexus

M/s. SUN Pharma ANZ Pty Ltd

Pharmaceutical Importer · Australia · Gastrointestinal Focus · $13.6M Total Trade · DGFT Verified

M/s. SUN Pharma ANZ Pty Ltd is a pharmaceutical importer based in Australia with a total trade value of $13.6M across 5 products in 4 therapeutic categories. Based on 291 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. SUN Pharma ANZ Pty Ltd sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

M/s. SUN Pharma ANZ Pty Ltd — Import Portfolio & Supplier Network

M/s. SUN Pharma ANZ Pty Ltd import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. SUN Pharma ANZ Pty Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$12.4M	466	100.0%

M/s. SUN Pharma ANZ Pty Ltd sources from 1 verified Indian supplier across 219 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Esomeprazole magnesium gastro	$2.0M	51
Apo-amoxycillin 500MG Pack:box20s	$724.7K	18
Apo-cephalexin cap 500MG Pack:box20s	$610.5K	14
Amoxycillin powder for oral	$347.9K	21
Atorvastatin sz 40MG Pack:box3x10s	$288.5K	8
Apo-cephalexin cap 250MG Pack:box20s	$247.3K	9
Atorvastatin sz 80MG Pack:box3x10s	$175.7K	6
Atorvastatin sz 20MG Pack:box3x10s	$170.4K	6
Meropenem ranbaxy 1GM Pack:5 vials	$150.0K	3
Apo-lansoprazole cap 30MG Pack:4x7s	$144.3K	4
Meropenem ranbaxy 500 MG Pack:5 vials	$130.5K	3
Ozole capsules 100MG Pack:4x7s	$125.0K	3
Ozole capsules 200MG Pack:4x7s	$123.7K	3
Aciclovir apotex tablets 200MG	$121.8K	4
Esomeprazole magnesium gastro resistanttablets 20 MG (apo-esomeprazole TAB 20MG(cfb) aust) Pack : box3x10s batch	$121.5K	3

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cephalexin	Antibiotics	$3.8M	95	1.1%	8
2	Esomeprazole	Gastrointestinal	$3.1M	63	0.7%	6
3	Magnesium	Vitamins & Supplements	$3.1M	63	0.9%	4
4	Omeprazole	Gastrointestinal	$3.1M	63	0.5%	8
5	Meropenem	Advanced Antibiotics	$350.0K	7	0.2%	2

M/s. SUN Pharma ANZ Pty Ltd imports 5 pharmaceutical products across 4 categories into Australia totaling $13.6M.

M/s. SUN Pharma ANZ Pty Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. SUN Pharma ANZ Pty Ltd is an Australian pharmaceutical importer and distributor, operating as a subsidiary of Sun Pharmaceutical Industries Limited, India's largest pharmaceutical company. Established in 1983, Sun Pharma has expanded its global footprint, with operations in over 100 countries, including Australia. The Australian subsidiary, formerly known as Ranbaxy Australia Pty Limited, rebranded to Sun Pharma ANZ Pty Ltd in February 2017. Headquartered at Suite 2.02, Level 2, 12 Waterloo Road, Macquarie Park, NSW 2113, Australia, the company plays a pivotal role in the distribution of pharmaceutical products across the Australian market.

2Distribution Network

Sun Pharma ANZ Pty Ltd's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Australia. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are robust, leveraging Sun Pharma's global infrastructure. This extensive network facilitates timely and reliable distribution, meeting the diverse needs of the Australian healthcare sector.

3Industry Role

In Australia's pharmaceutical supply chain, Sun Pharma ANZ Pty Ltd functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from its parent company in India, it ensures a steady supply of generic and specialty medicines to various stakeholders, including hospitals, pharmacies, and healthcare providers. This role is crucial in enhancing the accessibility and affordability of essential medications within the Australian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. SUN Pharma ANZ Pty Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sun Pharma ANZ Pty Ltd's sourcing strategy exhibits a high degree of concentration, with 100% of its pharmaceutical imports originating from Sun Pharmaceutical Industries Limited in India. This single-source dependency indicates a strategic choice to maintain consistency in product quality and supply chain efficiency. The substantial volume of imports—totaling $13.6 million USD across 291 shipments—reflects a stable and long-term relationship between the subsidiary and its parent company. Such concentration can streamline operations but may also expose the company to risks associated with supply chain disruptions in India.

2Supply Chain Resilience

The resilience of Sun Pharma ANZ Pty Ltd's supply chain is closely tied to its exclusive reliance on Sun Pharmaceutical Industries Limited in India. While this centralized sourcing strategy ensures uniformity in product quality, it also means that any disruptions in India's manufacturing or logistics could impact the Australian market. The company imports a diverse range of 219 unique pharmaceutical formulations, which may provide some buffer against supply chain interruptions. However, the lack of alternative suppliers suggests limited flexibility in responding to unforeseen challenges.

Strategic Implications

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory body overseeing the importation, supply, and distribution of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which sets forth the legislative framework for ensuring the safety, efficacy, and quality of medicines available in Australia. For Indian generics to be marketed in Australia, they must undergo a registration process with the TGA, which evaluates the product's compliance with Australian standards. (tga.gov.au)

2Import Licensing & GMP

Importing therapeutic goods into Australia requires compliance with the TGA's regulations, including obtaining the necessary import licenses. All medicines must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be legally imported, unless exempt. Manufacturers, including those in India, must adhere to Good Manufacturing Practice (GMP) standards recognized by the TGA, such as those from the European Union or the World Health Organization. This ensures that imported medicines meet the required quality standards for the Australian market. (tga.gov.au)

3Quality & Labeling

M/s. SUN Pharma ANZ Pty Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sun Pharma ANZ Pty Ltd's focus on importing products in the gastrointestinal, antibiotics, and vitamins & supplements categories aligns with significant market demand in Australia. The gastrointestinal category, comprising 46.3% of imports, addresses the prevalent need for treatments related to digestive health. Antibiotics (27.9%) and vitamins & supplements (23.2%) cater to the ongoing requirements for infectious disease management and general health maintenance, respectively. This strategic product selection ensures that the company meets critical healthcare needs within the Australian population.

2Sourcing Profile

Sun Pharma ANZ Pty Ltd's sourcing strategy is centered on generic drug formulations, with a preference for a diverse range of 219 unique products. This approach allows the company to offer a broad spectrum of therapeutic options to the Australian market. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for supplying these formulations. The company's exclusive reliance on Sun Pharmaceutical Industries Limited underscores the importance of maintaining a consistent and reliable supply chain.

3Market Positioning

Seller's Guide — How to Become a Supplier to M/s. SUN Pharma ANZ Pty Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Sun Pharma ANZ Pty Ltd, given the company's exclusive sourcing from Sun Pharmaceutical Industries Limited. To fill potential gaps in the current sourcing strategy, Indian exporters should focus on demonstrating compliance with Australian regulatory standards, including GMP certifications recognized by the TGA. Additionally, offering a diverse range of formulations that align with the therapeutic categories prioritized by Sun Pharma ANZ can enhance the attractiveness of such partnerships.

2Requirements & Qualifications

Indian exporters aiming to supply Sun Pharma ANZ Pty Ltd must obtain GMP certifications from recognized bodies, such as the European Union or the World Health Organization. Products must be registered with the TGA and listed in the ARTG. Labeling must be in English and comply with Australian standards, including specific information on dosage, active ingredients, and storage conditions. Adhering to these requirements ensures that products meet the quality and regulatory standards necessary for the Australian market.

3How to Approach

Frequently Asked Questions — M/s. SUN Pharma ANZ Pty Ltd

What products does M/s. SUN Pharma ANZ Pty Ltd import from India?

M/s. SUN Pharma ANZ Pty Ltd imports 5 pharmaceutical products across 4 categories. Top imports: Cephalexin ($3.8M), Esomeprazole ($3.1M), Magnesium ($3.1M), Omeprazole ($3.1M), Meropenem ($350.0K).

Who supplies pharmaceuticals to M/s. SUN Pharma ANZ Pty Ltd from India?

M/s. SUN Pharma ANZ Pty Ltd sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $12.4M).

What is M/s. SUN Pharma ANZ Pty Ltd's total pharmaceutical import value?

M/s. SUN Pharma ANZ Pty Ltd's total pharmaceutical import value from India is $13.6M, based on 291 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. SUN Pharma ANZ Pty Ltd focus on?

M/s. SUN Pharma ANZ Pty Ltd imports across 4 categories. The largest: Gastrointestinal (46.3%), Antibiotics (27.9%), Vitamins & Supplements (23.2%).

Get Full M/s. SUN Pharma ANZ Pty Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.